Harbour BioMed
Xiaoxiang Chen possesses extensive experience in the biopharmaceutical industry, currently serving as the Chief Development Officer at Harbour Biomed since November 2017, with responsibilities encompassing pre-clinical development, CMC, regulatory affairs, and clinical development for innovative drugs. Prior to this role, Xiaoxiang Chen held the position of Executive Vice President at Boehringer Ingelheim from January 2016 to November 2017, where expertise included regional medical leadership and oversight.
This person is not in any offices